Table 1. Patient characteristics in TCGA cohort and FUSCC cohort.
| Clinicopathologic characteristics | TCGA cohort, N=516 | FUSCC cohort, N=367 | ||
| Median or number | Range or percentage (%) | Median or number | Range or percentage (%) | |
| Age (years) | 60.5 | 26-90 | 56 | 21-86 |
| Follow-up length (months) | 40.6 | 0.1-151.2 | 60 | 7-110 |
| Gender | ||||
| Male | 337 | 65.31 | 248 | 67.57 |
| Female | 179 | 34.69 | 119 | 32.43 |
| Living status | ||||
| Dead | 172 | 33.33 | 135 | 36.78 |
| Alive | 344 | 66.67 | 232 | 63.22 |
| Progression | ||||
| Yes | 114 | 22.09 | 196 | 53.41 |
| No | 402 | 77.91 | 171 | 46.59 |
| ISUP grade | ||||
| I-II | 234 | 45.35 | 175 | 47.68 |
| II-IV | 277 | 53.68 | 192 | 52.32 |
| Unclear | 5 | 0.97 | ||
| pT stage | ||||
| T1 | 263 | 50.97 | 224 | 61.04 |
| T2 | 67 | 12.98 | 66 | 17.98 |
| T3 | 175 | 33.91 | 70 | 19.07 |
| T4 | 11 | 2.13 | 7 | 1.91 |
| pN stage | ||||
| N0 | 238 | 46.12 | 320 | 87.19 |
| N1 | 15 | 2.91 | 47 | 12.81 |
| Nx | 263 | 50.97 | ||
| M Stage | ||||
| M0 | 413 | 80.04 | 321 | 89.1 |
| M1 | 77 | 14.92 | 40 | 10.9 |
| Mx | 26 | 5.04 | 0 | 0 |
| AJCC stage | ||||
| Stage I | 257 | 49.81 | 218 | 59.4 |
| Stage II | 55 | 10.66 | 55 | 14.99 |
| Stage III | 122 | 23.64 | 40 | 10.9 |
| Stage IV | 82 | 15.89 | 54 | 14.71 |
| Laterality | ||||
| Left | 242 | 46.90 | 182 | 49.59 |
| Right | 273 | 52.91 | 185 | 50.41 |
| Bilateral | 1 | 0.19 | ||
| BMI | ||||
| <25 | 231 | 62.94 | ||
| >25 | 136 | 37.06 | ||
Abbreviation: TCGA: The Cancer Genome Atlas; FUSCC: Fudan University Shanghai Cancer Center; ISUP: The International Society of Urological Pathology; AJCC: American Joint Committee on Cancer; BMI: body mass index.